x
We use our own and third-party cookies to improve our services. If you continue browsing, we assume that you accept its use.
Information about cookiesAccept cookiesDecline cookies

Ready to market products

Potential License Out Opportunities
LUTRATE® Depot 3.75 mg

LUTRATE® Depot 3.75 mg

1 Month

Leuprolide Acetate

More details

LUTRATE® Depot 22.5mg

LUTRATE® Depot 22.5mg

3 Month

Leuprolide Acetate

More details

 Carbetocina GP-PHARM

Carbetocina GP-PHARM

Carbetocine

More details

Leuprolide Depot 7.5mg

Leuprolide Depot 7.5mg

Leuprolide Acetate

More details

NICTUR® Oral Solution

NICTUR® Oral Solution

Desmopressin360 µg/ml

More details

Triptorelin 3.75mg

Triptorelin 3.75mg

1 Month

Triptorelin Acetate

More details

Octreotide GP-Pharm

Octreotide GP-Pharm

Octreotide Acetate

More details

Somatostatin GP-Pharm

Somatostatin GP-Pharm

Somatostatin

More details

Irinotecan GP-Pharm

Irinotecan GP-Pharm

Irinotecan

More details

Oxaliplatin GP-Pharm

Oxaliplatin GP-Pharm

Oxaliplatin

More details

Gemcitabine GP-Pharm

Gemcitabine GP-Pharm

Gemcitabine

More details

Docetaxel GP-Pharm

Docetaxel GP-Pharm

Docetaxel

More details


Licensed-in products

For the Spanish Market
GALDAR®

GALDAR®

Letrozole

More details

GEPEX®

GEPEX®

Exemestane

More details

WIBICAL®

WIBICAL®

Bicalutamide

More details

AMENUR®

AMENUR®

Anastrozole

More details

ZUANDOL®

ZUANDOL®

Sildenafil

More details

ZUANTRIP®

ZUANTRIP®

Tamsulosin

More details

Paclitaxel GP-PHARM

Paclitaxel GP-PHARM

Paclitaxel

More details

UBC® RAPID TEST

UBC® RAPID TEST

Medical Device

More details


Research Projects

Opening Partnering for Co-Development & License
LUTRATE® Depot 45.0 mg 6 Month is a new depot formulation of Leuprolide Acetate, an LHRH agonist, used for the 6 month pallitative treatment of advanced prostate cancer. The product has completed its pre-clinical development and is ready to enter into a full clinical development.
GP Pharm is developing a generic multi-dose pen of the effective anabolic agent Teriparatide, which is used in the treatment of Osteoporosis. The product is being developed in a co-development arrangement with two different partners. The product will be available on European and US patent expiry and is available for licensing worldwide.
The generic development of Pegylated Liposomal Doxorubicine, used in the treatment of metastatic breast cancer, advanced ovarian cancer and multiple myeloma, has successfully completed its pre-clinical phase. The product is being developed in two different strengths (20 mg and 50 mg) and is ready to enter into a bio-equivalency study. The project is available for a co-development.
Sarcodoxome is a new liposomal Doxorubicine formulation aiming to decreases the carditoxicity of Doxorubicine. Sarcodoxome® therapeutic application include metastatic breast cancer, advanced ovarian cancer and multiple myeloma. The product has completed successfully its pre-clinical development and has been tested in Phase I and Phase II studies. The project is available for co-development and/or divestment.
Octreotide Depot MAR is a new formulation of development of in a polymer matrix micro-encapsulated Octreotide Acetate. It is developed for the 1 week treatment of chemo-therapy induced diarrhea. The product has been developed in two different stregths, i.e. 4 mg and 8 mg. It has successfully finished its pre-clinical development, demonstrating a significant decrease of chemotherapy induced diarrhea in animal models. The product is ready to enter into a full clinical development (Phase I to Phase III). The project is available for co-development and/or divestment.
Risperidone Depot is a generic development, in three strengths (25 mg, 37.5 mg and 50 mg) of an existing polymer micro-encapsulated formulation of Risperidone. Risperidone is applied for the treatment of Schizophrenia. The pre-clinical development has completed successfully the product is ready to enter into a bio-equivalency study. The project is available for divestment.

The content of the website you are trying to access may be considered as advertising regarding prescription medicines.

According to Spanish Royal Order 1416/1994 of 25 June regulating the advertising of medicinal products for human use and the Law 29/2006 on the guarantees and rational use of medicines and health products, in this section GP Pharm S.A. can only offer advertising content of prescription medicines to health personnel authorized to prescribe or dispense medicines.

The content of the website might contain information about drugs, medicines and/or therapeutic applications not approved in Spain.

I am a health professional authorized to prescribe or dispense, or a pharma company professional.

Accept | Cancel
Back to Top